Circulating homocysteine levels in sustained and white coat hypertension

Journal of Human Hypertension

Volumn 17, Issue 3, 2003, Pages 165-170

  Pierdomenico, S D ^a   Bucci, A ^a   Lapenna, D ^a   Lattanzio, F M ^a   Talone, L ^a   Cuccurullo, F ^a   Mezzetti, A ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Homocysteine; Sustained; White coat

Indexed keywords

CHOLESTEROL; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGE; AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; ANALYTICAL PARAMETERS; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET RESTRICTION; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; OCCUPATION; SUSTAINED HYPERTENSION; TRIACYLGLYCEROL BLOOD LEVEL; WHITE COAT HYPERTENSION;

ADULT; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; STRESS, PSYCHOLOGICAL;

EID: 0037352058     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001524     Document Type: Article

References (52)

1. Pickering TG et al. How common is white-coat hypertension? JAMA 1988; 259: 225-228.
2. Pierdomenico SD et al. White-coat hypertension in patients with newly diagnosed hypertension: Evaluation of prevalence by ambulatory monitoring and impact on cost of health care. Eur Heart J 1995; 16: 692-697.
3. White WB, Schulman P, MacCabe EJ, Dey HM. Average daily blood pressure, not office blood pressure, determines cardiac function in patients with hypertension. JAMA 1989; 261: 873-877.
4. Hoegholm A et al. Left ventricular mass and geometry in patients with established hypertension and white coat hypertension. Am J Hypertens 1993; 6: 282-286.
5. Gosse P, Promax H, Durandet P, Clementy J. 'White coat' Hypertension. No harm for the heart. Hypertension 1993; 22: 766-770.
6. Hoegholm A et al. Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension. Hypertension 1994; 24: 101-105.
7. Cavallini MC et al. Is white coat hypertension associated with arterial disease or left ventricular hypertrophy? Hypertension 1995; 26: 413-419.
8. Pierdomenico SD et al. Target organ status and serum lipids in patients with white coat hypertension. Hypertension 1995; 26: 801-807.
9. Pickering TG. Clinic measurement of blood pressure and white coat hypertension. In: Pickering TG (ed). Ambulatory Monitoring and Blood Pressure Variability. Science Press: London, 1991, pp 7.1-7.14.
10. Marchesi E et al. Metabolic risk factors in white coat hypertensives. J Hum Hypertens 1994; 8: 475-479.
11. Pierdomenico SD et al. Low-density lipoprotein oxidation and vitamins E and C in sustained and white-coat hypertension. Hypertension 1998; 31: 621-626.
12. Martinez MA et al. Frequency and determinants of white coat hypertension in mild to moderate hypertension: A primary care-based study. Am J Hypertens 1999; 12: 251-259.
13. Pierdomenico SD et al. Twenty-four-hour autonomic nervous function in sustained and 'white coat' hypertension. Am Heart J 2000; 140: 672-677.
14. Pierdomenico SD et al. Clinic and ambulatory heart rate in sustained and white-coat hypertension. Blood Press Monit 2001; 6: 239-244.
15. Verdecchia P et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793-801.
16. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: A 10-year follow-up study. Circulation 1998; 98: 1892-1897.
17. Fagard RH et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Circulation 2000; 102: 1139-1144.
18. Julius S et al. 'White coat' versus 'sustained' borderline hypertension in Tecumseh, Michigan. Hypertension 1990; 16: 617-623.
19. Cardillo C, De Felice F, Campia U, Folli G. Psycho-physiological reactivity and cardiac end-organ changes in white coat hypertension. Hypertension 1993; 21: 836-844.
20. Kuwajima I, Suzuki Y, Fujisawa A, Kuramoto K. Is white coat hypertension innocent? Structure and function of the heart in the elderly. Hypertension 1993; 22: 826-831.
21. Weber MA, Neutel JM, Smith DHG, Graettinger WF. Diagnosis of mild hypertension by ambulatory blood pressure monitoring. Circulation 1994; 90: 2291-2298.
22. Glen SK et al. White-coat hypertension as a cause of cardiovascular dysfunction. Lancet 1996; 348: 654-657.
23. Soma J et al. Left ventricular systolic and diastolic function assessed with two-dimensional and Doppler echocardiography in 'white coat' hypertension. J Am Coll Cardiol 1996; 28: 190-196.
24. Ferrara LA et al. Isolated office hypertension and end-organ damage. J Hypertens 1997; 15: 979-985.
25. Palatini P et al. Target-organ damage in stage 1 hypertensive subjects with white coat and sustained hypertension: Results from the HARVEST study. Hypertension 1998; 31: 57-63.
26. Zakopoulos N et al. Isolated clinic hypertension is not an innocent phenomenon: Effect on the carotid artery structure. Am J Hypertens 1999; 12: 245-250.
27. McGill Jr HC et al. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathological determinants of atherosclerosis in youth. Arterioscler Thromb Vasc Biol 1997; 17: 95-106.
28. Wilson PW et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
29. Malinow MF et al. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993; 87: 1107-1113.
30. Selhub J et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-291.
31. Perry IJ et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395-1398.
32. Giles WH et al. Total homocyst(e)ine concentration and the likelihood of nonfatal stroke. Results from the Third National Health and Nutrition Examination Survey, 1988-1994. Stroke 1998; 29: 2473-2477.
33. Matsui T et al. Elevated plasma homocysteine levels and risk of silent brain infarction in elderly people. Stroke 2001; 32: 1116-1119.
34. Stampfer MJ et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881.
35. Robinson K et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92: 2825-2830.
36. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.
37. Graham IM et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-1781.
38. Nygard O et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236.
39. Wald NJ et al. Homocysteine and ischemic heart disease. Results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-867.
40. Eikelboom JW et al. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363-375.
41. Ridker PM et al. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999; 281: 1817-1821.
42. Nappo F et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 281: 2113-2118.
43. Virdis A et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocysteinemia in normotensive subjects and patients with essential hypertension. J Am Coll Cardiol 2001; 38: 1106-1115.
44. Nygard O et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274: 1526-1533.
45. Malinow MR et al. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis 1995; 114: 175-183.
46. Sheu WHH, Lee WJ, Chen YT. Plasma homocysteine concentrations and insulin sensitivity in hypertensive subjects. Am J Hypertens 2000; 13: 14-20.
47. Pickering TG. Recommendations for the use of home (self) and ambulatory blood pressure monitoring. Am J Hypertens 1996; 9: 1-11.
48. Shipchandler MT, Moore EG. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott Imx Analyzer. Clin Chem 1995; 41: 991-995.
49. Altman DG. Practical Statistics for Medical Research. Chapman & Hall: London; 1995. pp 179-276.
50. Lip GYH et al. A pilot study of homocyst(e)ine levels in essential hypertension: Relationship to von Willebrand factor, an index of endothelial damage. Am J Hypertens 2001; 14: 627-631.
51. Tsioufis C et al. Relationships between new risk factors and circadian blood pressure variation in untreated subjects with essential hypertension. Am J Hypertens 2002; 15: 600-604.
52. Pierdomenico SD et al. Endothelial function in sustained and white coat hypertension. Am J Hypertens 2002; 15: 946-952.